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Abstract
Background: We investigated and compared the capacity of mean platelet volume (MPV) and other inflammatory
markers in detecting Crohn’s disease (CD) activity and differentiating CD patients from healthy controls.
Methods: MPV, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cells were measured
in 61 CD patients and 50 healthy subjects. Disease activity was assessed by the Crohn’s Disease Activity Index.
Results: A significant decrease in MPV was noted in patients with CD compared with healthy controls (P <0.0001),
but statistical difference was not found between active and inactive CD groups. In CD, no significant correlation
was found between MPV and other inflammatory markers. The overall accuracy of MPV (cutoff: 10.35 fl), CRP (cutoff:
4.85 mg/dl) and ESR (cutoff: 8.5 mm/hour) in differentiating CD patients from healthy controls was 76.6%, 65.8%
and 72.1% respectively. The overall accuracy of CRP (cutoff: 4.95 mg/dl) and ESR (cutoff: 16.5 mm/hour) in
determination of active CD was 80.3% and 73.8%.
Conclusions: MPV declined in CD patients compared with healthy subjects. MPV had the best accuracy in
determination of CD patients and healthy controls. MPV did not show a discriminative value in disease activity.
Keywords: Crohn’s disease, Mean platelet volume, C-reactive protein, Erythrocyte sedimentation rate, Inflammatory
bowel disease
Background
The pathogenesis of Crohn’s disease (CD) remains un-
clear [1,2]. Previous studies suggested that early detec-
tion of disease activity could significantly reduce the
mortality of CD [3,4]. Non-invasive tests, such as C-
reactive protein (CRP), erythrocyte sedimentation rate
(ESR) and fecal calprotectin, are therefore being increas-
ingly recognized as important markers for initial diagno-
sis and disease activity detection.
Recently, several studies have suggested that platelets
may be involved in the pathogenesis of CD [5-8]. In
addition, mean platelet volume (MPV) has been
reported to be influenced in CD [9,10], and has been
assumed a potential inflammatory marker and disease
activity indicator in several studies [10-12].
However, as these studies involved limited amounts of
enrolled patients or did not compare the differential
capacity of MPV with previous inflammatory markers,
the present study was designed to examine whether
MPV would be useful for differentiating CD patients
from healthy controls and evaluating CD activity. Fur-
thermore, we analyzed and compared the ability of MPV
with other inflammatory markers.
Methods
Patients
We prospectively collected 61 CD patients and 50
healthy subjects between March 2010 and September
2011 (Figure 1). The diagnostic criteria of CD were
mainly composed from standard clinical, radiological,
endoscopic and histopathologic findings.
The exclusion criteria were acute or chronic infection,
hypertension, endocrinological disorder, hematological
disease, heart failure, hepatic and renal disorder, cancer
and peripheral vascular disease [13]. None of the en-
rolled subjects had received anticoagulant medications,
NSAIDs or contraceptives.
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Full blood count (including MPV and white blood cells
(WBC)), CRP and ESR were performed on admission
(before prescribing any medications).
For MPV measurement in all enrolled patients, the
blood samples were anticoagulated by ethylenediamine
tetraacetic acid with wortmanin and tyrphostin [14], and
then treated with rapid processing (within <4 hours)
[14] and the same storage temperature [13,15]. For other
parameters, the measurement and process were carried
out according to standard laboratory practice.
To calculate the body mass index, height and weight
were recorded on admission for each individual. For CD
patients, the disease activity was defined according to
the Crohn’s Disease Activity Index (CDAI) score.
Patients were further divided into an active CD group
(CDAI >150) and an inactive CD group (CDAI <150)
(Figure 1).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
Software (version 5.01; GraphPad, San Diego, CA, USA).
All analyses were two-tailed and differences were con-
sidered statistically significant when P <0.05. For con-
tinuous variables, the mean and standard error of the
mean were calculated; Students’ t test was used to com-
pare variance between groups. For categorical variables,
percentages were provided and the chi-squared test was
used. Pearson analysis was used to calculate the correl-
ation between MPV and other inflammatory markers.
Receiver operating characteristic (ROC) curve analysis
was performed to identify optimal cutoff values for MPV
and other inflammatory markers. The overall accuracy
was also calculated by additional true-positive and true-
negative test results divided by all tests: (a + d) / (a + b +
c + d).
Ethical consideration
This study was approved by the Ethics Committee of
Jinling Hospital, and a written informed consent was
obtained from each enrolled participant.
Results
Differentiation of Crohn’s disease patients and healthy
controls
The demographic features of CD patients and healthy
controls are shown in Table 1. The distributions of age,
gender, smoking habit and body mass index were not
statistically significant between groups.
Table 2 demonstrates comparisons of all inflammatory
markers, including MPV, CRP, ESR and WBC. A significant
decline in MPV was noted in patients with CD compared
with healthy controls (9.55 ± 0.168 fl vs. 11.1 ± 0.160 fl,
P <0.0001). Meanwhile, CRP (13.4 ± 2.43 mg/dl vs.
2.89 ± 0.547 mg/dl, P <0.0001) and ESR (19.1 ± 2.15
mm/hour vs. 6.60 ± 0.431 mm/hour, P <0.0001) were
statistically higher in the CD group than those in the
control group. However, WBC appeared to be similar
in both groups (6.83 ± 0.377×10
9/l vs. 6.90 ±
0.342×10
9/l, P = 0.8881).
We further investigated the ability of MPV and other
markers in differentiating CD patients from healthy con-
trols. As shown in Table 3, the optimal cutoff value for
MPV was 10.35 fl, with sensitivity and specificity of
Figure 1 Study design. A total of 111 subjects were enrolled in the current study. Fifty healthy controls were differentiated with 61 Crohn’s
disease (CD) patients using mean platelet volume (MPV), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cells
(WBC). Furthermore, the 61 CD patients were divided into active (n = 29) and inactive (n = 32) groups and distinguished using the same
inflammatory biomarkers. All blood sample collections were obtained on admission (before any medication or procedure).
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(AUC): 0.8303). The overall accuracy of MPV in detect-
ing CD patients was 76.6%.
Moreover, ROC analysis also suggested 4.85 mg/dl and
8.5 mm/hour as optimal cutoff points for CRP (sensitiv-
ity: 52.5%, specificity: 82%, AUC: 0.6849) and ESR
(sensitivity: 68.9%, specificity: 76.0%, AUC: 0.7834) re-
spectively (Figure 1).
Differentiation of active and inactive Crohn’s disease
According to CDAI scores, patients with CD were
assigned into active and inactive groups. Notably, MPV
was similar between active and inactive CD patients
(9.52 ± 0.223 fl vs. 9.58 ± 0.251 fl, P = 0.8423) (Table 4).
However, CRP (21.8 ± 4.21 mg/dl vs. 5.75 ± 1.81 mg/dl,
P = 0.0012) and ESR (26.4 ± 3.26 mm/hour vs. 12.5 ±
2.33 mm/hour, P = 0.0011) of active CD patients were
significantly higher than those of inactive CD patients.
Spearman correlation analysis suggested that MPV did
not correlate with CRP (r = −0.022, P = 0.8671), ESR
(r = −0.059, P = 0.6518) or WBC (r = −0.1549, P =
0.2332) in patients with CD (Table 5).
We further performed ROC analysis to investigate the
capacity of all inflammatory markers in differentiating ac-
tive from inactive CD (Table 6 and Figure 2). The optimal
cutoff levels for CRP and ESR were 4.95 mg/dl (sensitiv-
ity: 82.8%, specificity: 78.1%, AUC: 0.7877) and 16.5 mm/
hour (sensitivity: 65.5%, specificity: 81.3%, AUC: 0.7909),
with 80.3% and 73.8% of overall accuracy respectively
(Figure 3). However, MPV did not show a statistically
discriminative value in differentiate active from inactive
CD (AUC: 0.5043, overall accuracy: 55.7%).
Discussion
In the present study we have demonstrated that the
MPV level was significantly lower in CD patients than
that in healthy participants. We also illustrated that
MPV was an accurate marker in distinguishing CD
patients from healthy controls. However, the MPV level
was statistically similar between active and inactive CD
patients, leading to a failure of detecting patients with or
without active disease.
Meanwhile, we demonstrated that CRP and ESR were
both higher in CD patients compared with healthy con-
trols, and higher in active compared with inactive CD
Table 1 Demographics of patients and controls
Crohn’s disease
(n = 61)
Control group
(n = 50)
P value
Age (years) 32.4 ± 1.59 34.0 ±1.44 0.133
Male (%) 40 (65.6%) 35 (70.0%) 0.686
Smoking 15 (24.6%) 11 (22.0%) 0.709
Body mass index (kg/m
2) 18.4 ± 0.526 19.3 ± 0.507 0.427
Active disease 29 (47.5%) ––
Age (%)
A1 (≤16 years) 9 (14.7%) ––
A2 (17–40 years) 37 (60.7%) ––
A3 (>40 years) 15 (24.6%) ––
Disease location (%)
L1 (ileal) 33 (54.1%) ––
L2 (colonic) 10 (16.4%) ––
L3 (ileocolonic) 18 (29.5%) ––
+ L4 (upper
gastrointestinal tract)
3 (4.92%) ––
Disease behavior (%)
B1 (inflammatory) 9 (14.7%) ––
B2 (stricturing) 32 (52.5%) ––
B3 (penetrating) 20 (32.8%) ––
+ P (perianal) 3 (4.92%) ––
Table 2 Comparison of MPV and other inflammatory
markers between Crohn’s disease and control groups
Crohn’s disease
(n = 61)
Control group
(n = 50)
P value
MPV (fl) 9.55 ± 0.168 11.1 ± 0.160 <0.0001
CRP (mg/dl) 13.4 ± 2.43 2.89 ± 0.547 <0.0001
ESR (mm/hour) 19.1 ± 2.15 6.60 ± 0.431 <0.0001
WBC (×10
9/l) 6.83 ± 0.377 6.90 ± 0.342 0.8881
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MPV, mean
platelet volume; WBC, white blood cells.
Table 3 Accuracy and ROC analyses of MPV and other
inflammatory markers in differentiate patients and
controls
AUC Sensitivity
(%)
Specificity
(%)
Overall
accuracy(%)
MPV (cutoff: 10.35) 0.8303 78.7 74.0 76.6
CRP (cutoff: 4.85) 0.6849 52.5 82.0 65.8
ESR (cutoff: 8.5) 0.7834 68.9 76.0 72.1
WBC (cutoff: 4.35) 0.5234 18.0 92 51.4
AUC, area under the curve; CRP, C-reactive protein; ESR, erythrocyte
sedimentation rate; MPV, mean platelet volume; ROC, receiver operating
characteristic; WBC, white blood cells.
Table 4 Comparison of MPV and other inflammatory
markers in patients with and without active disease
Active CD (n = 29) Inactive CD (n = 32) P value
MPV (fl) 9.52 ± 0.223 9.58 ± 0.251 0.8423
CRP (mg/dl) 21.8 ± 4.21 5.75 ± 1.81 0.0012
ESR (mm/hour) 26.4 ± 3.26 12.5 ± 2.33 0.0011
WBC (×10
9/l) 6.42 ± 0.413 7.19 ± 0.613 0.3047
CD, Crohn’s disease; CRP, C-reactive protein; ESR, erythrocyte sedimentation
rate; MPV, mean platelet volume; WBC, white blood cells.
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ESRwas lower than that of MPV in detecting CD
patients, they were still effective in determination of ac-
tive CD patients.
Moreover, we found that MPV was not correlated with
CRP, ESR or WBC in patients with CD. WBC was not
an effective indicator in distinguishing CD patients from
healthy subjects and active from inactive CD patients.
CD is characterized by chronic, transmural intestinal
inflammation in which periods of remission with vari-
able length are interrupted by relapse episodes. Previous
studies have demonstrated that appropriate and effective
therapy could significantly control symptoms, maintain
remission, prevent relapse, improve quality of life and
reduce mortality [3,16]. The early determination of diag-
nosis and detection of disease activity are therefore es-
sential for tailoring therapy [17].
As invasive techniques, including endoscopic, radio-
logical and histopathologic methods, are routinely used
for diagnostic decision and disease activity supervision,
an ideal non-invasive test is increasingly expected for ini-
tial diagnosis and identification of disease activity [18].
CRP is a valuable inflammatory marker in inflamma-
tory bowel disease (IBD), especially CD [17,19]. Prior
studies suggested a sensitivity range for uncovering IBD
between 50 and 60% [20,21]. In our study, CRP displayed
a high accuracy for differentiating CD patients from
healthy controls and for distinguishing patients with and
without active disease (65.8% and 80.3% respectively).
ESR and WBC are both nonspecific markers of inflam-
mation. Although they could adjust to and reflect the se-
verity of inflammation, low sensitivity and specificity of
Table 5 Correlation between MPV and other
inflammatory markers in Crohn’s disease
MPV r value P value
CRP −0.022 0.8671
ESR −0.059 0.6518
WBC −0.1549 0.2332
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MPV, mean
platelet volume; WBC, white blood cells.
Table 6 Overall accuracy and ROC analyses of MPV and
other inflammatory markers in differentiating Crohn’s
disease
AUC Sensitivity
(%)
Specificity
(%)
Overall
accuracy (%)
MPV (cutoff: 8.80) 0.5043 31.0 78.1 55.7
CRP (cutoff: 4.95) 0.7877 82.8 78.1 80.3
ESR (cutoff: 16.5) 0.7909 65.5 81.3 73.8
WBC (cutoff: 7.20) 0.5474 72.4 40.6 55.7
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MPV, mean
platelet volume; ROC, receiver operating characteristic; WBC, white blood cells.
Figure 2 Mean platelet volume and other inflammatory
markers in differentiate Crohn’s disease patients and controls.
Receiver operating characteristic (ROC) curves. The optimal cutoff
value for mean platelet volume (MPV) was 10.35 fl (sensitivity: 78.7%,
specificity: 74.0%, area under the curve: 0.8303), with 76.6% overall
accuracy.
Figure 3 Mean platelet volume and other inflammatory
markers in differentiate active and inactive Crohn’s disease.
Receiver operating characteristic (ROC) curves. The optimal cutoff
levels for C-reactive protein (CRP) and erythrocyte sedimentation
rate (ESR) were 4.95 mg/dl (sensitivity: 82.8%, specificity: 78.1%, area
under the curve (AUC): 0.7877) and 16.5 mm/hour (sensitivity: 65.5%,
specificity: 81.3%, AUC: 0.7909), with 80.3% and 73.8% overall
accuracy respectively. MPV did not show a statistically discriminative
value in differentiating active from inactive Crohn’s disease (CD)
(AUC: 0.5043, overall accuracy: 55.7%).
Liu et al. European Journal of Medical Research 2012, 17:27 Page 4 of 7
http://www.eurjmedres.com/content/17/1/27gastrointestinal inflammatory status were reported in
previous studies [19,22]. However, in the present study,
ESR performed as a notable marker in the detection of
CD patients (overall accuracy: 72.1%) and in distinguish-
ing active from inactive CD (overall accuracy: 73.8%).
Recently, a series of stool tests, such as fecal lactofer-
rin, calprotectin and elastase, were investigated as novel
inflammatory markers. Even though they may be super-
ior to CRP or ESR with higher sensitivity and specificity
in detecting gastrointestinal inflammation [17,23,24],
they are not specific markers for IBD; and they are in-
convenient and unpleasant for stool sampling.
The link between MPV and inflammation has been
well investigated in the literature [13,25]. Previous series
of case–control and cohort studies have discovered sev-
eral important confounders of MPV. Smoking and ex-
posure to nicotine were key factors that would
significantly influence platelet morphology and size, and
could be confounded by sex, age and duration of smok-
ing [13]. In the current study, the age, sex and smoking
histories were statistically similar between healthy con-
trols and patients with CD (Table 1). However, the dur-
ation of smoking was not registered and calculated in
this study, leading to a difficulty in excluding the influ-
ence of duration of smoking on MPV. Nevertheless, as
the percentage of participants with a current or previous
smoking history was <25% in both healthy control
(22.0%) and CD (24.6%) groups, the influence of dur-
ation of smoking on MPV was dramatically restricted.
Hypertension [13,26] and diabetes [27,28] were con-
firmed closely correlated with large platelet size, respect-
ively. To prevent their influence on MPV, we excluded
patients with hypertension, heart failure, hepatic and
renal disorder, vascular disease, endocrinological dis-
order and hematological disease. Obesity was also found
to be associated with elevated MPV [13,29]. However,
the normal and similarity of body mass index in both
healthy controls and CD patients eliminated the poten-
tial influence of obesity on MPV.
Platelets, which are frequently complicated with
thromboembolic risks, may play a crucial role in the
pathogenesis of IBD [30-33]. The statistically significant
declined MPV in CD patients observed in the present
study is in accordance with findings of prior studies
[9,10], suggesting that MPV may be helpful in clinical
practice [34,35].
To our knowledge, prior studies have never analyzed
and reported a positive result of MPV in differentiating
CD patients from healthy volunteers using ROC analysis.
Our study, for the first time, discovered a preliminary
but inspiring finding that MPV could be used as a good
biomarker in distinguishing CD from healthy controls
(Table 3). We are aware that our finding is not sufficient
for employing MPV solely in this differential diagnosis,
but our finding could provide a suggestion for clinical
physicians to pay attention to the value of MPV and take
it into account when making decisions of differential
diagnosis.
The similar MPV between active and inactive CD
patients observed in our study is not in agreement with
those in previous studies. The absence of any correlation
between MPV and other inflammatory markers in our
study supported the hypothesis that MPV was not in a
close relationship with CD activity. In the studies by Jar-
emo and Sandberg-Gertzen [10] and Kapsoritakis and
colleagues [12], an activity-dependent diversity of MPV
was reported. The reason for this discrepancy is unclear;
we assume that the amount of enrolled patients in these
studies was limited, and large-sample studies are
expected to investigate the real diversity between active
and inactive CD patients.
Our study raised several interesting and meaningful
controversies that are worthy of discussions and further
investigations.
Firstly, we raised controversy about the correlation be-
tween MPV and other inflammatory biomarkers in CD.
Although the issue of MPV shifts in inflammatory dis-
orders has been extensively covered in recent publica-
tions, studies in the current literature investigating the
association of MPV and CD are still limited. Among
them, studies discussing the correlation between MPV
and other regular inflammatory biomarkers (including
CRP, ESR and WBC) in CD are even fewer.
The only and most worthy-of-mention study was pub-
lished in 2001. Kapsoritakis and colleagues collected data
for 66 patients with CD and 38 healthy volunteers, and
found a negative correlation of MPV with CRP, ESR and
WBC [12]. However, they did not analyze and compare
the cutoff point, sensitivity, specificity and overall accur-
acy of MPV and other biomarkers.
Our results are not in accordance with their findings.
As no statistical correlation between MPV and other in-
flammatory biomarkers was confirmed in our study, an
obvious and meaningful controversy appeared. While
the sample size was similar between our study (n = 61)
and that of Kapsoritakis and colleagues (n = 66), further
studies are expected to uncover the real relationship be-
tween MPV and other biomarkers. This confirmation of
relationship is pivotal in determining the role of MPV in
the inflammatory course in CD.
Secondly, we raised a controversy about the decisive
value of MPV in the determination of activity in CD.
The similarity of MPV between active and inactive CD
in our study is in contrast with several previous remark-
able studies. Jaremo and Sandberg-Gertzen collected
data for 18 ulcerative colitis patients, nine CD patients
and 18 healthy volunteers, and reported an association
of lower MPVs with active IBD [10]. However, this
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cantly hampered the value of their conclusions. Yuksel
and colleagues recruited data for 61 ulcerative colitis
patients and 27 healthy controls, and suggested that
decreased MPV may be an indicator for increased disease
activity in patients with ulcerative colitis [35]. However,
they did not collect data for CD patients or provide any
information regarding MPV in indicating CD activity.
Douda and colleagues collected data for 56 CD
patients and found that decreased MPV is an independ-
ent laboratory marker of clinical disease activity [36].
However, MPV’s predictive value is inferior compared
with the total platelet count, CRP and CDAI. The latter
finding is partly in accordance with our findings. We
also discovered that MPV was inferior to CRP and ESR
in determination of activity in CD (see Table 6), but it is
still a challenge for clinical physicians to find more evi-
dence to prove a definite association between MPV and
disease activity.
There has been sufficient evidence derived from nu-
merous prospective and retrospective studies suggesting
MPV is a key predictor of thrombotic events in various
disorders [13], including cardiovascular disease [37],
cerebrovascular disease [38,39], venous thromboembol-
ism [40] and other disorders [41,42].
In IBD, low-sized platelet with an increase of platelet
count has been a typical manifestation for both CD and
ulcerative colitis [13]. Meanwhile, both a prothrombotic
condition and a hypercoagulable state are established
features of IBD [43]. Microaggregates and microinfarc-
tion of mesenteric vessels unveiled a potential role of
platelet as an inflammatory cell in the pathogenesis of
CD [8,13]. Wakefield and colleagues demonstrated in
their study a consecutive process of microinfarction in
mesenteric vasculature [44]. This process was initiated
by vascular injury, followed by focal arteritis, fibrin de-
position and arterial occlusion at muscularis mucosa.
Subsequently, tissue infarction and mucosal ulceration
were assumed to be a possible chain of events in the
pathogenesis of CD [45]. Notably, the above course of
events depended on several key factors – including
glycoprotein IIb/IIIa, which is a platelet surface glyco-
protein, and platelet surface template for factors V and
VIII, which were previously known as platelet factor 3
[46]. Platelets were therefore proposed to be involved, at
least partly, in the formation of microinfarction and the
pathogenesis of CD [45].
An increased activation of platelet was confirmed
by the expression of surface activation markers including
P-selectin, GP53 and β-thromboglobulin [43,47]. More-
over, various factors (such as IL-3, IL-6 and thrombo-
poietin) were responsible for the platelet activation and
participated in the stimulation of thrombopoiesis [48].
The reduced size of platelets in CD suggested a possible
mechanism in which large activated platelets were con-
sumed or sequestrated in the intestinal vasculature [49].
We are aware of limitations to our study. First, this is
a single-center study, leading to a potential selection
bias. Second, as only 61 CD cases and 50 healthy sub-
jects were enrolled in our study, the sample size might
be too small to detect the real diversity of MPV between
active and inactive CD patients.
Conclusions
Our study demonstrated a decline of MPV in CD patients
compared with healthy controls. We also compared MPV
with other inflammatory markers, including CRP, ESR and
WBC, and provided the discriminative talent of MPV and
recommended MPV as the best marker for differentiating
CD patients from healthy subjects. Finally, we suggested
that it should be cautious to use MPV as a marker in de-
termination of CD activity. Large multicenter studies are
expected to resolve the controversy.
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